scholarly journals Tacrolimus and “Mini” Methotrexate is an Effective Regimen for Prevention of Graft-Versus-Host-Disease In Children Undergoing Umbilical Cord Blood Transplant

2009 ◽  
Vol 15 (2) ◽  
pp. 81 ◽  
Author(s):  
S.S. Kelly ◽  
P. Kelly ◽  
S.P. Hunger ◽  
J.R. Wingard
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Graft Versus Host Disease ◽  
Umbilical Cord Blood ◽  
Host Disease ◽  
Graft Versus Host ◽  
Effective Regimen ◽  
Cord Blood Transplant

scholarly journals Third-party umbilical cord blood–derived regulatory T cells prevent xenogenic graft-versus-host disease

Cytotherapy ◽  
2014 ◽  
Vol 16 (1) ◽  
pp. 90-100 ◽  
Author(s):  
Simrit Parmar ◽  
Xiaoying Liu ◽  
Shawndeep S. Tung ◽  
Simon N. Robinson ◽  
Gabriel Rodriguez ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Graft Versus Host Disease ◽  
Umbilical Cord Blood ◽  
Third Party ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease

Blood ◽  
1996 ◽  
Vol 88 (3) ◽  
pp. 795-802 ◽  
Author(s):  
JE Wagner ◽  
J Rosenthal ◽  
R Sweetman ◽  
XO Shu ◽  
SM Davies ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Graft Versus Host Disease ◽  
Umbilical Cord Blood ◽  
Unrelated Donor ◽  
Hematopoietic Stem ◽  
Host Disease ◽  
Graft Versus Host ◽  
Unrelated Donors ◽  
Acute Graft

Abstract To reduce the morbidity and mortality associated with unrelated donor bone marrow (BM) transplantation and potentially extend the pool of suitable donors, cryopreserved unrelated donor umbilical cord blood was considered as an alternate source of hematopoietic stem cells for transplantation. Patients with leukemia, BM failure syndrome, or inborn error of metabolism were eligible for a phase I clinical trial designed to estimate the risk of graft failure and severe acute graft-versus- host disease after transplantation of umbilical cord blood from unrelated donors. As of December 21, 1995, unrelated donor umbilical cord blood was used to reconstitute hematopoiesis in eighteen patients aged 0.1 to 21.3 years weighing 3.3 to 78.8 kg with acquired or congenital lympho-hematopoietic disorders or metabolic disease. Patients received either HLA-matched (n = 7) or HLA-1 to 3 antigen disparate (n = 11) grafts collected and evaluated by the New York Blood Center (New York, NY). The probability of engraftment after unrelated donor umbilical cord blood transplantation was 100% with no patient having late graft failure to date. The probability of grade III-IV acute graft-versus-host disease at 100 days was 11%. With a median follow-up of 6 months (range, 1.6 to 17 months); the probability of survival at 6 months is 65% in this high risk patient population. We conclude that cryopreserved umbilical cord blood from HLA-matched and mismatched unrelated donors is a sufficient source of transplantable hematopoietic stem cells with high probability of donor derived engraftment and low risk of refractory severe acute graft-versus-host disease. Limitations with regard to recipient size and degree of donor HLA disparity remain to be determined.

Sign in / Sign up

Export Citation Format

Share Document